Press Detail





News: Biotest AG: Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services

News: Biotest AG / Key word(s): Miscellaneous
Biotest AG: Biotest strengthens its position in the German haemophilia
market with the introduction of new patient support services

11.10.2017 / 07:00
The issuer is solely responsible for the content of this announcement.



/
PRESS RELEASE

Biotest strengthens its position in the German haemophilia market with the
introduction of new patient support services

- Biotest supports home treatment with a team of specialised nurses

- New approach aims to tailor haemophilia therapy to individual patient
needs

- Biotest starts with the important haemophilia market Germany

Dreieich, 11 October 2017. Medically controlled home treatment allows
patients with haemophilia to live an almost normal life and to minimise the
risk of spontaneous bleeding. A prerequisite for a long-term safe treatment
is a consistent and correct application of the preparations at home. With
the new haemoPRO service, the support by a nurse, Biotest aims to provide
patients, their relatives and caregivers with the necessary safety in the
use of their haemophilia therapy. In this way, Biotest ensures that all
patients are optimally treated according to their individual therapeutic
scheme. The new service gives Biotest the opportunity to improve patient
quality of life in its most important and largest haemophilia market in
Germany.

The Biotest program haemoPRO supports where despite detailed briefings by
physicians uncertainties in the correct application of the coagulation
factor remain. In the haemophilia centres, the patients and their relatives
are prepared for the home treatment and are extensively trained to work
sterile, to properly dissolve the powder and apply intravenous injection.
However, some patients and their relatives may still find it difficult to
implement what has been learned in the centre in the private environment.
Parents have uncertainties to find a suitable vein for their injection in
their child. It is also possible that older patients are not able to inject
themselves due to additional diseases. Furthermore, there are also physical
limitations, such as an arm fracture, which temporarily makes a home
treatment impossible.

In such and similar cases, haemoPRO's service is open to all patients
treated with Biotest coagulation factors. If the patient agrees to the
attendance of the haemoPRO service offered by the physician, a haemoPRO
nurse will contact the patient and arrange visits. haemoPRO keeps the
physician up-to-date on the training results after each contact. Thus, the
patient's quality of life can be improved in close consultation with the
treating physician.

About Haemophilia
As a lifelong inherited bleeding disorder, haemophilia affects about 1 in
10,000 people worldwide. Haemophilia is one of a number of such disorders
that prevent blood from clotting properly. People with haemophilia
experience prolonged internal bleeding that can result from a seemingly
minor injury. Bleeding into joints and muscles causes severe pain and
disability while bleeding into major organs, such as the brain, can cause
death. Treating the bleeding episodes involves the prompt and proper use of
clotting factor concentrates. Haemophilia A is caused by a deficiency of
clotting factor VIII. Therefore, intravenously administered therapeutic
factor VIII is often recognised as a foreign protein (antigen) by the
patient's immune system. As a consequence up to 30% of patients with severe
haemophilia develop antibodies against the therapeutic factor VIII. These
antibodies are called inhibitors because they reduce or eliminate the
therapeutic effect of factor VIII. Most inhibitors develop during early
childhood and compromise the ability to effectively prevent or manage
haemorrhages, resulting in a greater rate of disability, morbidity,
complications and costs of therapy. The formation of inhibitors is the most
serious complication of today's haemophilia treatment. Avoiding the risk of
inhibitor development would be the most effective prerequisite for a
continuous therapy enabling haemophilia patients to live an almost normal
life without irreversible joint damage. For more information on haemophilia
and FVIII, please visit the World Federation of Haemophilia website at
http://www.wfh.org/en/page.aspx?pid=646

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,
Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.




11.10.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de



Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange



End of News DGAP News Service


617413 11.10.2017